Partner content
Unlocking investment in UK life sciences through manufacturing
Government-backed funding towards manufacturing within the sector can drive regional growth, and benefit patients.
ByLife sciences
Partner content
A prescription for success: improving the UK’s access to new medicines
Labour has pledged to put Britain at the front of the queue for medical breakthroughs; achieving that goal will require…
By
Partner content
Individually rare, collectively common – how do we transform the lives of people with rare diseases?
Clear national policy, collaboration with patients, and reviewing progress are key to tackling diagnosis, treatment and care challenges.
Partner content
How to turn the life sciences “superpower” ambition into reality
Partnership between the NHS, industry and research institutes is crucial to enable the UK to reach its clinical research potential.
By
Partner content
How can the UK boost its life sciences sector to improve patient outcomes?
Britain has a strong background in pharmaceuticals and clinical trials but is struggling to achieve its full potential.
Partner content
Strengthening the UK’s clinical trial ecosystem
Why pharmaceutical companies play a role in driving progress.
By
Partner content
Can the UK be a life sciences superpower?
The answer is yes, but the window of opportunity is closing.
By
The Policy Ask with Richard Torbett: “The pandemic really demonstrated what the pharma industry does for the world”
The chief executive of the Association of the British Pharmaceutical Industry on joining Horizon, R&D policy, and his morning run.
By
Partner content
How digital innovation can unlock a healthier future
The rapid advancement of technology must be used to fight disease.
By